PI3K inhibitor · small molecule
taselisib
1 active trials across 3 of our biomarkers, targeting PI3Kα. Not approved for any biomarker on marked.bio yet.
Also known as GDC-0032.
Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.
Biomarkers
| Biomarker | Active trials | All trials | Furthest active phase |
|---|---|---|---|
| PIK3CA activating mutation | 1 | 4 | Phase 2 |
| KRAS G12C | 0 | 1 | – |
| KRAS G12D | 0 | 1 | – |
Trials
1 of 4 trials shown
-
Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)
Patients must have a PIK3CA mutation as determined via the MATCH Master Protocol
PIK3CA activating mutationAdvanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
-
A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy
taselisibfulvestrant FDA EU
A valid cobas PIK3CA mutation result by central testing is required
PIK3CA activating mutationBreast Cancer
-
PIPA: Combination of PI3 Kinase Inhibitors and PAlbociclib
KRAS mutations) may be considered, depending on emerging preclinical and clinical data on these novel an…
KRAS G12CKRAS G12DPIK3CA activating mutationAdvanced Solid Tumours, Breast Cancer
-
A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
fulvestrant FDA EUtaselisibletrozolemidazolam
Phase I (Cohort X): Participants with PIK3CA-mutant tumors and measurable disease per RECIST v1.1
PIK3CA activating mutationSolid Cancers, Non-Hodgkin's Lymphoma
No trials match these filters.